Importantly, we found that overexpression and knockdown of CD2AP increased and decreased TRIM5 levels, respectively, and that downregulation of TRIM5 reversed the activated NF-κB signaling in GBM cells with CD2AP overexpression. The gene discussed is NFKB1; the disease is glioblastoma.